We use cookies on our website to help provide you with the best online experience possible. If you continue and accept all cookies, you will receive all of the cookies that we use on the site. If you would like to adjust which cookies you receive you can change these settings at any time by following the links provided at the bottom of every page of the site. Find out more on how we use cookies and how you can change your settings.
Viral Safety Strategy for mAbs: Prevent, Detect, Remove
Viral safety is a critical aspect of biopharmaceutical/biologics production and relies on the well-established principles of “prevent, detect and remove” to assure drug safety for patients. These principles are the foundation of every viral safety strategy and depend on the approaches outlined below:
Prevent: Careful selection and pretreatment of raw materials to prevent adventitious viruses from entering processes Detect: Testing for the presence of viruses and other adventitious agents in cell banks, raw materials, and process intermediates Remove: Implementation of technologies to remove or inactivate viruses and execute clearance studies to demonstrate process safety
There is no single viral safety solution that works for every process. Working with a partner with experience in all aspects of viral safety assurance can accelerate your drug development process and provide peace of mind.
Watch our series of tech talk videos to know more about viral safety risk mitigation strategies
Viral Risk Mitigation Strategies
Prevent Upstream Contamination
Detect Viral Contamination
Remove Viruses Downstream
Learn more about viral safety risk mitigation strategies
Collateral
An overview of the global regulatory framework to ensure the viral safety of biologics, including the latest guidance documents from the US FDA, WHO, European Pharmacopoeia and ICH.